Wedbush Expects Reduced Earnings for Revolution Medicines

Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - Wedbush decreased their Q2 2025 earnings per share estimates for Revolution Medicines in a report released on Thursday, May 8th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per share of ($1.17) for the quarter, down from their prior estimate of ($1.07). Wedbush currently has a "Outperform" rating and a $67.00 target price on the stock. The consensus estimate for Revolution Medicines' current full-year earnings is ($3.49) per share. Wedbush also issued estimates for Revolution Medicines' Q3 2025 earnings at ($1.21) EPS, Q4 2025 earnings at ($1.24) EPS, FY2025 earnings at ($4.76) EPS, Q1 2026 earnings at ($1.27) EPS, Q2 2026 earnings at ($1.24) EPS, Q3 2026 earnings at ($1.24) EPS, Q4 2026 earnings at ($1.27) EPS, FY2026 earnings at ($5.02) EPS, FY2027 earnings at ($4.77) EPS, FY2028 earnings at ($2.96) EPS and FY2029 earnings at $1.82 EPS.

Other equities research analysts have also issued research reports about the company. Needham & Company LLC reiterated a "buy" rating and issued a $57.00 target price on shares of Revolution Medicines in a research note on Thursday. Guggenheim lowered their price objective on Revolution Medicines from $87.00 to $80.00 and set a "buy" rating for the company in a research note on Thursday. Stifel Nicolaus lowered their price objective on Revolution Medicines from $78.00 to $64.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. HC Wainwright raised their price objective on Revolution Medicines from $72.00 to $73.00 and gave the company a "buy" rating in a research note on Monday, March 3rd. Finally, Oppenheimer raised their price objective on Revolution Medicines from $70.00 to $75.00 and gave the company an "outperform" rating in a research note on Thursday. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat, Revolution Medicines presently has a consensus rating of "Buy" and an average price target of $67.17.

Revolution Medicines Stock Performance

RVMD stock opened at $40.58 on Monday. Revolution Medicines has a 1 year low of $29.17 and a 1 year high of $62.40. The firm has a market cap of $7.56 billion, a P/E ratio of -11.30 and a beta of 1.11. The stock has a 50-day simple moving average of $37.36 and a 200-day simple moving average of $43.39.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.01). During the same quarter last year, the business posted ($0.70) earnings per share.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. IFP Advisors Inc acquired a new position in Revolution Medicines during the 4th quarter valued at approximately $34,000. Sterling Capital Management LLC raised its stake in Revolution Medicines by 588.7% during the 4th quarter. Sterling Capital Management LLC now owns 1,956 shares of the company's stock valued at $86,000 after acquiring an additional 1,672 shares in the last quarter. Farther Finance Advisors LLC raised its stake in Revolution Medicines by 368.3% during the 4th quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company's stock valued at $90,000 after acquiring an additional 1,613 shares in the last quarter. Kapitalo Investimentos Ltda bought a new stake in Revolution Medicines during the 4th quarter valued at $104,000. Finally, GF Fund Management CO. LTD. bought a new stake in Revolution Medicines during the 4th quarter valued at $154,000. Institutional investors and hedge funds own 94.34% of the company's stock.

Insider Transactions at Revolution Medicines

In related news, insider Mark A. Goldsmith sold 11,738 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $39.04, for a total transaction of $458,251.52. Following the completion of the transaction, the insider now owns 441,564 shares in the company, valued at $17,238,658.56. The trade was a 2.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Jack Anders sold 1,864 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $72,770.56. Following the transaction, the chief financial officer now owns 115,006 shares of the company's stock, valued at $4,489,834.24. This represents a 1.59% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 16,660 shares of company stock worth $650,406. 8.00% of the stock is currently owned by corporate insiders.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.